NCT06218511Active, not recruitingPhase 1
A phase I trial of IMA970A plus Montanide in combination with Durvalumab (anti-PD-L1) in patients with very early, early and intermediate stage of hepatocellular carcinoma after any standard treatments.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 8 Apr 2025
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- First submitted
- 21 Oct 2024
- Start date
- 21 Nov 2022
- Lead sponsor
- IRCCS Istituto Nazionale Tumori Fondazione Pascale
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT06218511
- EU CT number
- 2024-518298-33-00
- EudraCT number
- 2021-002910-15
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| IRCCS Istituto Nazionale Tumori Fondazione Pascale Coordinator of this site? Confirm its status | Naples | Italy | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.